Viral load responses to HAART is an independent predictor of a new AIDS event in late stage HIV infected patients: Prospective cohort study

Journal of Translational Medicine

Volumn 3, Issue , 2005, Pages

  Kazanjian, Powel ^a,b   Wei, Wei ^b   Brown, Morton ^b   Gandhi, Tejal ^a   Amin, Kamal ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

AIDS; CD4; HAART; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FOLLOW UP; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OUTPATIENT DEPARTMENT; PREDICTION; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; VIRUS INHIBITION; VIRUS LOAD;

EID: 27744587855     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-3-40     Document Type: Article

References (35)

1. Palella F, Delaney K, Moorman A: Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998, 338:853-60.
2. Ledergerber B, Egger B, Erard V, et al: AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. JAMA 1999, 282:2220-6.
3. Ferrer E, Santamarina E, Santin M, et al: Progression to AIDS/Death is higher in patients initiating ARV with CD4 counts < 350 [abstract]. In 10th Conference on Retroviruses and Opportunistic Infections; Boston, MA. 2003:910.
4. Van Sighem AI, van de Wiel MA, Ghani A, et al, on behalf of the ATHENA cohort study group: Mortality and progression to AIDS after starting highly antiretroviral therapy. AIDS 2003, 17:2227-36.
5. Egger M, May M, Chene G, et al, ART Cohort Collaboration: Prognosis of HIV-1 Infected patients starting Highly Active Antiretroviral Therapy: A Collaborative Analysis of Prospective Studies. Lancet 2002, 360:119-29.
6. Sterling TR, Chaisson RE, Keruly J, et al: Improved Outcomes with Earlier Initiation of Highly Active Antiretroviral Therapy among Human Immunodeficiency Virus-Infected Patients who Achieve Durable Virologic Suppression: Longer Follow-Up of an Observational Cohort Study. J Infect Dis 2003, 188:1659-65.
7. Tierney C, Lathey JL, Christopherson C, et al: Prognostic value of baseline HIB type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis 2003, 187:144-8.
8. Wood E, Hogg R, Yip B, et al: Higher baseline levels of plasma HIV type 1 RNA are associated with increased mortality after initiation of triple drug antiretroviral therapy. J Infect Dis 2003, 188:1421-5
9. de Wolfe R, Spijkerman I, Schellekens P: AIDS prognosis based on HIV-1 RNA, CD4+ T cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997, 11:1799-806.
10. Tarwater PM, Gallant JE, Mellors JW, et al: Prognostic value of plasma HIV RNA among highly active antiretroviral users. AIDS 2004, 18:2419-23.
11. Raffanti SP, Fusco JS, Sherrill BH, et al: Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy. J Acquir Immune Defic Syndr 2004, 37:1147-54.
12. ART Cohort Collaboration: Prognostic importance of initial response in HIV-1 infected patients starting patent antiretroviral therapy: analysis of prospective studies. Lancet 2003, 362:679-86.
13. Kaplan JE, Hanson DL, Jones JL, et al: Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS 2001, 15:1831-36.
14. Olsen CH, Gatel J, Ledergerber B, et al: Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005, 19:319-30.
15. Ledergerber B, Egger M, Opravil M, et al: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863-68.
16. Belec L, Piketty C, Si-Mohammed A, et al: High levels of drug resistant HIV in patients exhibiting increasing CD4 T cell counts despite virologic failure of protease inhibitor-containing ARV. J Inf Dis 2000, 181:1808-12.
17. Kaufmann G, Furrer H, Perrin L, et al: Low Baseline CD4 T-cell Count and Higher Age Predict Poor CD4 T-cell Recovery in Treated HIV-1 Infected Individuals Suppressing HIV-1 RNA to Levels <1000 copies/mL for 5 Years [abstract]. In 11th Conference on Retroviruses and Opportunistic Infections; SF, CA. 2004:557.
18. Department of Health and Human Services [DHHS] Guidelines [http:// www.aidsinfo.nih.gov].
19. Centers for Disease Control and Prevention: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992, 41 (RR-17):1-19.
20. Deeks SG, Hecht FM, Swanson M, et al: HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999, 13:F35-F43.
21. King MS, Bernstein BM, Walmsley SL, et al: Baseline HIV-1 RNA level and CD4 count predict time to loss of virologic response to nelfinavir but not lopinavir/ritonavir in antiretroviral therapy-naïve patients. J Inf Dis 2004, 190:280-4.
22. Ribaudo H, Downey G, Fischl M, et al: Factors Associated with Virologic Failure and Their Impact on Treatment Outcomes: An Analysis of Virologic Failure in ACTG 388 [abstract]. In 11th Conference on Retroviruses and Opportunistic Infections; SF, CA. 2004:553.
23. Paredes R, Mocroft A, Kirk O, et al: Predictors of virologic success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe. Arch Intern Med 2000, 160:1123-32.
24. Mocroft A, Ledergerber B, Viard JP, et al: Time to Triple Drug Class Failure after Initiation of HAART [abstract]. In 11th Conference on Retroviruses and Opportunistic Infections; SF, CA. 2004:554.
25. + Cells or High Values of HIV-1 RNA Concentration, Not by Choice of Treatment with Nevirapine or Efavirenz [abstract]. In 11th Conference on Retroviruses and Opportunistic Infections; SF, CA. 2004:550.
26. PLATO Collaboration: Predictors of trend in CD4-positive T cell count and mortality among HIV-1 infected individuals with biological failure to all three antiretroviral drug classes. Lancet 2004, 364:51-62.
27. Kuritzkes DR: Effect of Antiretroviral Resistance on Response to Treatment-Experienced Patients. The AIDS Reader 2003, 13:S5-11.
28. Schwarcz S, Hsu L: AIDS in the HAART Era: the Extent and Characteristics of Late HIV Testers [abstract]. In 11th Conference on Retroviruses and Opportunistic Infections; SF, CA. 2004:864.
29. Nash D, Manning SE, Ramaswamy C: Descriptive Epidemiology of HIV/AIDS in New York City: Incorporation of Newly Available Population-based Surveillance Data on HIV (non-AIDS), 2001 [abstract]. In 11th Conference on Retroviruses and Opportunistic Infections; SF, CA. 2004:87.
30. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report. 1998, 9:28.
31. Moorman AC, Von Bargen JC, Palella FJ, et al: Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:182-8.
32. Mocroft A, Lederberger B, Katlama C, et al, EuroSIDA study group: Decline in AIDS and Death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-39.
33. Ives N, Gazzard BG, Easterbrook PJ: Changing pattern of AIDS defining illnesses with introduction of Highly active antiretroviral therapy in a London clinic. J Infect 2001, 42:134-9.
34. Sabin C, D'Arminio Monforte A, May M, et al: The Changing incidence of Clinical AIDS events in 12,574 treatment naive patients starting HAART [abstract]. In 10th Conference on Retroviruses and Opportunistic Infections; Boston, MA. 2003:569.
35. Yeni PG, Hammer SM, Hirsch MS, et al: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004, 292:251-65.